| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 43,068 | 16,516 | ||
| Short-term investments | 12,419 | 24,117 | ||
| Accounts receivable, net | 81,047 | 79,931 | ||
| Inventory, net | 70,025 | 72,965 | ||
| Prepaid expenses and other current assets | 22,841 | 17,394 | ||
| Total current assets | 229,400 | 210,923 | ||
| Property and equipment, net | 12,960 | 13,683 | ||
| Right-of-use lease assets | 708 | 1,401 | ||
| Other assets | 5,882 | 6,083 | ||
| Total assets | 248,950 | 232,090 | ||
| Convertible notes payable, net | - | 149,806 | ||
| Accounts payable | 12,017 | 12,037 | ||
| Notes payable, net | - | 25,398 | ||
| Accrued clinical and manufacturing liabilities | 19,663 | 17,135 | ||
| Accrued payroll and employee liabilities | 8,748 | 6,471 | ||
| Other accrued liabilities | 48,500 | 46,215 | ||
| Current lease liabilities | 780 | 1,539 | ||
| Total current liabilities | 89,708 | 258,601 | ||
| Non-current notes payable, net | 107,487 | - | ||
| Non-current convertible notes payable, net | 32,176 | - | ||
| Other non-current liabilities | 4,694 | 747 | ||
| Total liabilities | 234,065 | 259,348 | ||
| Common stock | 1,833 | 1,533 | ||
| Series a convertible preferred stock | 7,862 | - | ||
| Additional paid-in capital | 1,942,025 | 1,890,550 | ||
| Accumulated other comprehensive loss | 0 | -1 | ||
| Accumulated deficit | -1,936,835 | -1,919,340 | ||
| Total stockholders' equity (deficit) | 14,885 | -27,258 | ||
| Total liabilities and stockholders' equity (deficit) | 248,950 | 232,090 | ||
HERON THERAPEUTICS, INC. DE (HRTX)
HERON THERAPEUTICS, INC. DE (HRTX)